Cyclacel Pharmaceuticals Inc (CYCC)

4.18
0.06 1.34
NASDAQ : Health Care
Prev Close 4.12
Open 4.13
Day Low/High 4.13 / 4.35
52 Wk Low/High 3.60 / 12.60
Volume 38.50K
Avg Volume 817.80K
Exchange NASDAQ
Shares Outstanding 4.27M
Market Cap 18.16M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results

Conference Call Scheduled March 28, 2017 at 4:30 p.m. EDT

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, A Novel Cancer-Specific Mechanism Of Action, In Research Published In JNCI

CYC065 found effective against lung cancer cell lines including those with KRAS mutations

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.

Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.58 on the day. This compares to an average yield of 10.81% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia

-Preclinical Data Presented at the 28th EORTC-NCI-AACR Symposium-

Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down

Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down

The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Conference Call Scheduled for November 14, 2016 at 4:30 p.m. ET

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.51 on the day. This compares to an average yield of 10.90% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today

Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today

Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.

Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish

Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish

H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Cyclacel Announces Reverse Stock Split

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT